Figure 5.
Figure 5. CD16/γ-transduced T-cell clone can proliferate and produce cytokines only when the CD16 molecule is crosslinked in the presence of mAbs and target cells. (A) Proliferative activity of CD16/γ-transduced EBV-specific T-cell clone no.24 was assessed after 72 hours of coculture with autologous or allogeneic BLCL and IL-2 (40 IU/mL) in the presence of either rituximab (anti-CD20, 2 μg/mL) or herceptin (anti–HER-2, 10 μg/mL). Soluble anti-CD20 mAb also was tested at the higher concentrations that are indicated. (B) The CD16/γ transduced EBV-specific T-cell clone no.7 (which recognizes through its TCR the autologous BLCL but not an allogeneic mismatch BLCL) and produced TNFα after PMA + ionomycin stimulation (i) was activated only after CD16 crosslinking in the presence of the allogeneic BLCL and 0.02 μg/mL of anti-CD20 (ii, iii) but remained unstimulated by the soluble mAb at a concentration of 50 to 50 000 superiors (iv-vii).

CD16/γ-transduced T-cell clone can proliferate and produce cytokines only when the CD16 molecule is crosslinked in the presence of mAbs and target cells. (A) Proliferative activity of CD16/γ-transduced EBV-specific T-cell clone no.24 was assessed after 72 hours of coculture with autologous or allogeneic BLCL and IL-2 (40 IU/mL) in the presence of either rituximab (anti-CD20, 2 μg/mL) or herceptin (anti–HER-2, 10 μg/mL). Soluble anti-CD20 mAb also was tested at the higher concentrations that are indicated. (B) The CD16/γ transduced EBV-specific T-cell clone no.7 (which recognizes through its TCR the autologous BLCL but not an allogeneic mismatch BLCL) and produced TNFα after PMA + ionomycin stimulation (i) was activated only after CD16 crosslinking in the presence of the allogeneic BLCL and 0.02 μg/mL of anti-CD20 (ii, iii) but remained unstimulated by the soluble mAb at a concentration of 50 to 50 000 superiors (iv-vii).

Close Modal

or Create an Account

Close Modal
Close Modal